Reviva pharmaceuticals provides update on clinical development pipeline

Enrollment remains on pace for reviva's phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the us with enrollment set to begin at sites in europe and india in q3 2022
RVPH Ratings Summary
RVPH Quant Ranking